9/26
08:51 am
onco
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement [Yahoo! Finance]
High
Report
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement [Yahoo! Finance]
9/26
08:30 am
onco
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
Medium
Report
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
9/26
08:15 am
onco
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
Medium
Report
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
9/22
08:43 am
onco
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM [Yahoo! Finance]
High
Report
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM [Yahoo! Finance]
9/22
08:00 am
onco
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
Medium
Report
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM